ImmuCell(US:ICCC)2026-03-30 21:34Manufacturing Capacity and Production - ImmuCell Corporation increased its manufacturing capacity from approximately 3 million units in 2023 to 4.6 million units in 2025, reflecting a growth strategy for future production [15]. - The company invested $11.0 million from 2019 to December 31, 2025, increasing annual production capacity for the First Defense® product line from approximately 2.2 million units in 2018 to approximately 4.6 million units in 2025 [65]. - Manufacturing capacity expanded from approximately 4.1 million units in 2024 to 4.6 million units in 2025 [114]. - ImmuCell plans to increase manufacturing capacity ahead of demand by improving yields and investing in major capacity expansion leveraging former Re-Tain® assets [19]. Product Sales and Financial Performance - Product sales grew by 4.3% in 2025 compared to 2024, with gross margin improving from 30% to 41% of product sales, despite a non-cash write-off of inventories amounting to approximately 2.4% of full-year product sales [16]. - For the year ended December 31, 2025, product sales increased to $27,644,174, representing a growth of 4% compared to $26,493,169 in 2024 [115]. - Gross profit for the year ended December 31, 2025, was $11.4 million, a 44% increase compared to $7.9 million in 2024 [119]. - The net loss for 2025 was $1,040,027, an improvement from a net loss of $2,156,629 in 2024, showing a reduction of about 51.7% [187]. - Net operating income for 2025 was $1.6 million, a significant increase compared to a net operating loss of $1.6 million in 2024 [52]. Market and Competitive Landscape - The market for biological scours preventatives exceeded $90 million in 2025, marking a 14% increase from 2024, with a cumulative average growth rate of 6.9% since 2021 [19]. - Approximately 55% of U.S. calves are not currently protected by biological scours prevention products, indicating significant market expansion opportunities [24]. - The market for calf scours preventatives and treatments is highly competitive, with First Defense® typically priced higher than competing vaccine products [51]. - The First Defense® product line represents approximately 29% of total market spend in 2025, up from 24% in 2021, and is used to protect about 15% of calves on preventative programs, an increase from 13% in 2021 [24]. Product Development and Innovation - The company initiated commercial sales of a new spray-dried format of First Defense Technology® in bulk powder during 2025, expanding its product offerings [32]. - The First Defense® products deliver 3.3 to 5.6 times the level of neutralizing antibodies against major scours pathogens compared to leading vaccines, highlighting their competitive advantage [37]. - The company is focusing on the First Defense® product line, which utilizes hyperimmunized bovine colostrum to provide Immediate Immunity™ against neonatal calf diarrhea [113]. - The company has significantly increased the number of farms from which it purchases colostrum, but a reduction in farm capacity could hinder production [95]. Financial Position and Debt Management - Aggregate outstanding debt as of December 31, 2025, totaled $9.1 million, with principal and interest payments of approximately $2 million and $1.5 million due in 2026 and 2027, respectively [53]. - The debt service coverage (DSC) ratio was 2.65 for the year ended December 31, 2025, compared to 0.73 for 2024, with a minimum required DSC ratio of 1.35 [56]. - The company had an aggregate debt outstanding of $9.1 million as of December 31, 2025, down from $10.5 million in 2024 [134]. Regulatory and Compliance Issues - The company is not currently commercializing Re-Tain®, which is regulated by the FDA, and has passed an in-depth USDA inspection in August 2025 [45]. - Regulatory requirements for the First Defense® product line may lead to interruptions in sales if the USDA does not approve requalification of the Reference Standard [72]. - The company is subject to periodic audits by the IRS and other taxing authorities, with no income tax examinations for years before 2022 [154]. Management and Operational Changes - Significant management changes occurred, including the hiring of a new President and CEO and the creation of a Chief Financial Officer position [117]. - The company is dependent on key personnel, with 73 employees, and the loss of any key employee could adversely affect operations [80]. Risks and Challenges - The company faces risks related to colostrum supply, including potential disease outbreaks and competition from other companies offering higher premiums for colostrum [69]. - Recent contamination events and equipment failures have negatively impacted production output and gross margin, leading to scrapped inventory and reduced sales [68]. - The company faces competition from larger firms like Elanco, Merck, and Zoetis, which have greater resources and may offer lower-priced alternatives [81]. - The company is exposed to economic risks in the dairy and beef industries, which could negatively affect its addressable market [76]. Shareholder and Stock Information - The average daily trading volume of the company's common stock was 16,939 shares during the 20-day period ended March 20, 2026 [88]. - The company's market capitalization was approximately $54.9 million as of March 20, 2026, which is about two times its product sales of $27.6 million for the year ended December 31, 2025 [88]. - As of March 20, 2026, the company had 15,000,000 common shares authorized and 9,046,799 common shares outstanding [109]. Financial Reporting and Internal Controls - The independent registered public accounting firm has expressed an unqualified opinion on the financial statements of the company [177]. - Management evaluated the effectiveness of disclosure controls and procedures as of December 31, 2025, concluding they were effective [156]. - There were no changes in internal control over financial reporting that materially affected the company during the quarter ended December 31, 2025 [159].